The U.S. Department of Health and Human Services (HHS) has announced it will exercise “enforcement discretion” regarding state-licensed pharmacies that manufacture and sell six specific peptides: BPC-157, KPV, epitalon, MOTS-c, semax, and TB-500. Under HHS leadership, the federal agency will refrain from legal action against pharmacies providing these products to the general public, despite none of them holding approval from the U.S. Food and Drug Administration.

These Six Peptides Have Not Yet Received FDA Approval

The lack of FDA approval stems from a fundamental absence of sufficient data demonstrating that these compounds are safe or effective for human use. These short chains of connected amino acids essentially present a high-stakes gamble for any consumer, as there is no guarantee of safety or efficacy. A closer look reveals the specific uncertainties associated with each of the six substances.

First is BPC-157, an abbreviation for “Body Protection Compound-157.” Consisting of 15 amino acids and originally isolated from gastric juice, proponents claim it aids tissue repair and stimulates new blood vessel growth. Although laboratory and rodent experiments point toward these benefits, rigorous randomized clinical trials in humans are lacking. Because angiogenesis and tissue development can theoretically influence tumor growth, and because interactions with other medications remain unknown, major athletic bodies and the World Anti-Doping Agency (WADA) have banned BPC-157.

Another compound, KPV, comprises the amino acids lysine (K), proline (P), and valine (V). Typically found at the terminus of alpha-melanocyte-stimulating hormone—a natural regulator of inflammatory and immune responses—KPV is viewed as an anti-inflammatory agent. While cell cultures and murine tests indicate reduced colon and skin inflammation, animal studies also reveal side effects such as fatigue, headaches, gastrointestinal upset, and severe allergic reactions, leaving its true human safety profile unverified.

Epitalon is a synthetic tetrapeptide composed of alanine, glutamic acid, aspartic acid, and glycine, designed to mimic epithalamin from bovine pineal glands. Theorized to promote longevity by activating telomerase to maintain chromosomal telomeres, normalize circadian rhythms via melatonin production, and support immune resilience, epitalon lacks comprehensive human backing. Furthermore, cancer cells can exploit telomerase pathways to multiply, and synthetic injections carry risks of immune or allergic rejection.

MOTS-c stands for mitochondrial open reading frame of the 12S rRNA type-c. Encoded by mitochondrial genomes, this 16-amino-acid peptide is touted for mimicking exercise, enhancing glucose uptake in skeletal muscle, and regulating metabolism. However, manipulating metabolic processes without robust human clinical trials carries hazards, including dangerously low blood sugar levels. WADA has likewise banned MOTS-c use in competitive athletics.

Semax is a synthetic heptapeptide derived from a fragment of adrenocorticotropic hormone. Promoted as a nootropic or cognitive enhancer capable of increasing brain-derived neurotrophic factor and influencing neurotransmitters, it is utilized in Russia for managing strokes and memory disorders. Nevertheless, altering neurological pathways without extensive clinical trials introduces significant, unmeasured risks.

Finally, TB-500 is a synthetic heptapeptide mirroring a fragment of Thymosin Beta-4, a natural 43-amino-acid protein aiding cellular structure and tissue repair. Promoted as a recovery peptide for muscle and tendon injuries, it lacks human clinical data to confirm its safety, while raising familiar concerns regarding immune triggers and angiogenesis-related tumor proliferation.

There Is Already A ‘Gray Market’ For These 6 Peptides

A thriving gray market has long existed for these compounds, with sellers often evading FDA oversight by labeling the items as strictly for research use only. Proponents argue that permitting compounding pharmacies to distribute them will shift supply away from unregulated channels toward more transparent environments, allowing the FDA to mandate identity and purity testing alongside adverse event reporting.

Critics, however, point to ongoing questions regarding potential conflicts of interest within the HHS and FDA. As policy shifts under the administration of President Donald Trump and HHS Secretary Robert F. Kennedy Jr., public health experts continue to debate whether this regulatory pivot will protect consumers or invite a wave of unproven therapies and financial exploitation.